Breakingviews on Twitter
Search League Tables

Monday, 30 May 2016

Elan's $3.25 bln deal reduces risk - and raises it

One in hand and two in bush

The biotech is selling part of its 50 pct stake in its blockbuster drug, and main asset, Tysabri, to partner Biogen. That should maximize Elan’s profit: this reduces the incentive Biogen has to sell competing drugs. The danger is the cash burns a hole in the company’s pocket.

This content is for Subscribers only

To access full content you must be a subscriber. Please use the following link to request a trial.

Sign In

(Launches in a new window)